BioGenCell Completes $16M in Seed Funding
- BioGenCell, a Netanya, Israel-based biotechnology company, raised $16M in Seed funding
- The round was led by Marius Nacht
- The company intends to use the funds to accelerate its development efforts
- The company is a biotechnology company that develops technology for using stem cells from the patient’s own blood to treat microvascular diseases
- Bio GenCell’s medical platform focuses on the needs of patients and physicians
- The current product treats severe limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers
